The results show that daraxonrasib prolonged survival, slowed disease progression and led to tumour shrinkage more frequently than chemotherapy, whilst causing mainly mild, manageable side effects.
Background The Kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation is no longer an “elusive” target, having become an important therapeutic target in non-small cell lung cancer (NSCLC). The approvals of sotorasib and adagrasib have significantly altered the second-line treatment algorithm. This systemat...
Julia Piekarz, Natalia Picheta, Jakub Pobideł et al.· Frontiers in Oncology· 0 citations
The classification of endometrial cancer based on histological examination often fails to accurately predict treatment outcomes for patients. The Cancer Genome Atlas (TCGA) has proposed a new molecular model that more accurately identifies the tumour subtype, enabling more precise treatment. However, its implementation...
Natalia Gierulska, Julia Orzelska, Katarzyna Lachowska et al.· International Journal of Mol...· 0 citations
Dato-DXd demonstrates robust clinical activity in patients with BC, providing superior disease control with a favorable safety profile compared to conventional chemotherapy, and preclinical data suggest that the induction of ICD may contribute to reshaping a heterogeneous TME.
Julia Piekarz, Natalia Picheta, Jakub Pobideł et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
